![](/img/cover-not-exists.png)
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch
Awan, Farrukh T., Hillmen, Peter, Hellmann, Andrzej, Robak, Tadeusz, Hughes, Steven G., Trone, Denise, Shannon, Megan, Flinn, Ian W., Byrd, John C.Volume:
167
Language:
english
Journal:
British Journal of Haematology
DOI:
10.1111/bjh.13061
Date:
November, 2014
File:
PDF, 229 KB
english, 2014